Comparing Breyanzi vs Tecartus
| Breyanzi (lisocabtagene maraleucel) | Tecartus (brexucabtagene autoleucel) |
|
|---|
| Breyanzi (lisocabtagene maraleucel) | Tecartus (brexucabtagene autoleucel) |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Chronic Lymphocytic Leukemia, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma. Breyanzi may also be used for purposes not listed in this... View more |
Prescription only
Prescribed for Acute Lymphoblastic Leukemia, Mantle Cell Lymphoma. Tecartus may also be used for purposes not listed in this medication guide. |
||||||||
| More about Breyanzi (lisocabtagene maraleucel) | More about Tecartus (brexucabtagene autoleucel) | ||||||||
| Ratings & Reviews | |||||||||
|
Be the first to share your experience with this drug. |
Be the first to share your experience with this drug. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||
|
View all Breyanzi side effects |
View all Tecartus side effects |
||||||||
| Drug Class | |||||||||
| Generic Availability | |||||||||
|
N/A |
N/A |
||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||
View all Breyanzi prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms | |||||||||
|
|
||||||||
| Brand Names | |||||||||
|
N/A |
N/A |
||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||
|
N/A |
N/A |
||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | |||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||
| Drug Interactions | |||||||||
|
A total of 297 drugs are known to interact with Breyanzi:
|
A total of 307 drugs are known to interact with Tecartus:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
| Disease Interactions | |||||||||
| First Approval Date | |||||||||
|
N/A |
N/A |
||||||||
| WADA Class View classifications | |||||||||
|
N/A |
N/A |
||||||||
| More Information | |||||||||
| Patient Resources | |||||||||
| Professional Resources | |||||||||
| Related Treatment Guide | |||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Rituxan
Rituxan infusion is used to treat certain leukemias and lymphomas and some non-cancer conditions ...
Truxima
Truxima is used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid ...
Monjuvi
Monjuvi is used for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or follicular ...
Kymriah
Kymriah is used to treat acute lymphoblastic leukemia (ALL) that is relapsing or refractory in ...
Polivy
Polivy (polatuzumab vedotin-piiq) is a targeted treatment that may be used to treat diffuse large ...
Yescarta
Yescarta is a CAR T-cell treatment used to treat relapsed or refractory large B-cell lymphoma ...
Xpovio
Xpovio is used to treat multiple myeloma (MM) or relapsed/refractory diffuse large B-cell lymphoma ...
Zynlonta
Zynlonta (loncastuximab tesirine) is used to treat relapsed or refractory diffuse large B-cell ...
Columvi
Columvi is used to treat certain types of diffuse large B-cell lymphoma (DLBCL) or large B-cell ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.